Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity;Frühe hämatologische Veränderungen während der Radiotherapie beim Prostatakarzinom prädiktiv für späte Miktions- und Darmbeschwerden

Strahlentherapie und Onkologie

Volumn 191, Issue 10, 2015, Pages 771-777

  Pinkawa, Michael ^a   Ribbing, Carolina ^a   Djukic, Victoria ^a   Klotz, Jens ^a   Holy, Richard ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

C reactive protein; Hemoglobin; Intensity modulated radiotherapy; Predictive assays; Quality of life

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; EARLY DIAGNOSIS; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTESTINE FUNCTION; LABORATORY TEST; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PREDICTIVE VALUE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RISK FACTOR; TOXICITY; UROGENITAL TRACT DISEASE; ADJUVANT THERAPY; BLOOD; CANCER STAGING; GASTROINTESTINAL TRACT; HEMOGLOBIN DETERMINATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION RESPONSE; UROGENITAL SYSTEM; VERY ELDERLY;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; C-REACTIVE PROTEIN; CYTOKINES; GASTROINTESTINAL TRACT; HEMOGLOBINOMETRY; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; UROGENITAL SYSTEM;

EID: 84942374074     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-015-0841-3     Document Type: Article

References (26)

1. Blank KR, Cascardi MA, Kao GD (1999) The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 44:317–321
2. Bolla M, Van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027
3. Budäus L, Bolla M, Bossi A et al (2012) Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 61:112–127
4. Christensen E, Pintilie M, Evans KR et al (2009) Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 15:5576–5583
5. Christiansen H, Saile B, Hermann RM et al (2007) Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer. J Cancer Res Clin Oncol 133:297–304
6. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
7. Henriquez-Hernandez LA, Bordon E, Pinar B et al (2012) Prediction of normal tissue toxicity as part of the individualized treatment with radiotherapy in oncology patients. Surg Oncol 21:201–206
8. Indaram AV, Visvalingam V, Locke M et al (2000) Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am J Gastroenterol 95:1221–1225
9. Kim YJ, Cho KH, Pyo HR et al (2014) Radical prostatectomy versus external beam radiotherapy for localized prostate cancer: comparison of treatment outcomes. Strahlenther Onkol (in press) published in 2015; Strahlenther Onkol 191: 321-329
10. Koc M, Taysi S, Sezen O et al (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26:1494–1497
11. Li LY, Yang M, Gao X et al (2009) Prospective comparison of five mediators of the systemic response after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer. BJU Int 104:1063–1067
12. Lohm G, Lütcke J, Jamil B et al (2014) Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: long-term follow-up of a single center survey. Strahlenther Onkol 190:727–731
13. Lopes CO, Callera F (2012) Three-dimensional conformal radiotherapy in prostate cancer patients: rise in interleukin 6 (IL-6) but not IL-2, IL-4, IL-5, tumor necrosis factor-alpha, MIP-1-alpha, and LIF levels. Int J Radiat Oncol Biol Phys 82:1385–1388
14. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
15. Peinemann F, Grouven U, Bartel C et al (2011) Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60:881–893
16. Petersen SE, Bentzen L, Emmertsen KJ et al (2014) Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer. Radiother Oncol 111:94–99
17. Pinkawa M, Holy R, Piroth MD et al (2010) Consequential late effects after radiotherapy for prostate cancer—a prospective longitudinal quality of life study. Radiat Oncol 5:27
18. Pinkawa M, Eble MJ, Mottaghy FM (2011) PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev Anticancer Ther 11:1033–1039
19. Pinkawa M, Holy R, Piroth DM et al (2011) Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 186:600–606
20. Pinkawa M, Djukic V, Klotz J et al (2014) Hematologic chnages during radiation therapy are dependent on treatment volume. Future Oncol 10:835–843
21. Pinkawa M, Schubert C, Excobar-Corral N et al (2014) Application of a hydrogel spacer for postoperative slavage radiotherapy of prostate cancer. Strahlenther Onkol (in press) published in 2015: Strahlenther Onkol 191: 375-379
22. Schaake W, Wiegman EM, de Groot M et al (2014) The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. Radiother Oncol 110:284–290
23. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962
24. Wei JT, Dunn RL, Litwin MS et al (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905
25. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930
26. Zachariah B, Jacob SS, Gwede C et al (2001) Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int J Radiat Oncol Biol Phys 50:465–472